

# **Genitourinary Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product (Urologicals, Hormonal Therapy, Gynecological, Anti-infectives, Others), By Indication (Prostate cancer, Ovarian cancer, Bladder cancer, Cervical cancer, Renal cancer, Erectile dysfunction, Urinary tract infections, Urinary incontinence & overactive bladder, Sexually transmitted diseases, Interstitial cystitis, Hematuria, Benign prostatic hyperplasia), By Drug Type (Hormonal Therapy, Impotence Agents, Urinary Antispasmodics, Urinary pH Modifiers, Uterine Relaxants, Uterine Stimulants), By Region, and Competition**

<https://marketpublishers.com/r/GEEC8E08BD7FEN.html>

Date: November 2023

Pages: 181

Price: US\$ 4,900.00 (Single User License)

ID: GEEC8E08BD7FEN

## **Abstracts**

Global Genitourinary Drugs Market has valued at USD 27.80 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 2.53% through 2028. The global genitourinary drugs market refers to the pharmaceutical sector dedicated to developing, manufacturing, and distributing medications for diseases and conditions affecting the genitourinary system. This system encompasses the urinary tract and the male and female reproductive organs.

## **Key Market Drivers**

## Increasing Disease Prevalence

The global genitourinary drugs market has experienced substantial growth in recent years, thanks in large part to the increasing prevalence of genitourinary diseases and conditions. As populations age, lifestyles change, and healthcare awareness rises, the demand for pharmaceutical solutions to address these conditions is on the upswing.

Genitourinary diseases encompass a wide range of conditions, including urinary tract infections, sexually transmitted infections, and various types of cancer, such as prostate and bladder cancer. What ties these diverse conditions together is the commonality of the urinary and reproductive systems being affected. With urbanization, changing dietary habits, and sedentary lifestyles becoming more prevalent globally, the incidence of genitourinary diseases has been steadily rising.

The demographic shift towards an aging population is a central factor contributing to the increased prevalence of genitourinary diseases. As people age, the risk of developing these conditions rises significantly. The elderly population often faces issues like urinary incontinence, erectile dysfunction, and prostate problems, driving the demand for drugs and treatments.

Modern lifestyles have introduced various risk factors for genitourinary diseases. Factors such as increased stress levels, poor dietary choices, smoking, and limited physical activity can contribute to the development of these conditions. Additionally, environmental factors and exposure to carcinogens may lead to the development of genitourinary cancers, further fueling the need for pharmaceutical interventions.

Changing sexual behaviors and an increase in the number of sexual partners have contributed to the spread of sexually transmitted infections (STIs) such as gonorrhea, chlamydia, and syphilis. The rising prevalence of STIs necessitates effective medications and treatments, propelling the genitourinary drugs market.

The surge in disease prevalence has spurred pharmaceutical companies to invest heavily in research and development. This investment has led to the development of more effective and targeted therapies, including antibiotics for urinary tract infections, hormone therapies for erectile dysfunction, and immunotherapies for genitourinary cancers. Patients and healthcare providers now have access to a broader range of treatment options, further driving market growth.

Increased healthcare awareness and the importance of early diagnosis and treatment have encouraged more individuals to seek medical care for genitourinary health issues. Regular check-ups and early intervention can lead to better outcomes, which, in turn, increase the demand for pharmaceutical solutions.

### Advances in Drug Development

Advances in drug development have been instrumental in reshaping the landscape of the global pharmaceutical industry. Within this realm, the global genitourinary drugs market has experienced significant growth, thanks to innovation and the introduction of new and improved treatments.

One of the primary ways in which advances in drug development contribute to the growth of the genitourinary drugs market is by yielding medications with enhanced efficacy and safety profiles. Pharmaceutical companies invest heavily in research and development to create drugs that are more targeted, have fewer side effects, and produce better outcomes for patients. As new genitourinary drugs enter the market, they provide healthcare providers with more effective tools to combat a range of conditions, including urinary tract infections, erectile dysfunction, and genitourinary cancers.

Precision medicine has revolutionized the way genitourinary conditions are treated. Advances in genomics and personalized medicine have enabled healthcare professionals to tailor treatments to individual patients based on their genetic makeup and disease characteristics. This approach not only improves patient outcomes but also enhances the effectiveness of genitourinary drugs. For example, targeted therapies and immunotherapies have become increasingly prevalent in the treatment of genitourinary cancers, demonstrating the potential of precision medicine in this field.

Drug development advances have led to the creation of novel drug classes specifically designed to address genitourinary conditions. For example, the introduction of phosphodiesterase type 5 (PDE5) inhibitors revolutionized the treatment of erectile dysfunction, offering a non-invasive and highly effective solution. Similarly, advancements in hormone therapies have provided new options for individuals facing issues related to hormonal imbalances within the genitourinary system.

In addition to pharmaceuticals, drug development has spurred advancements in minimally invasive surgical procedures. These procedures have become increasingly popular for treating genitourinary conditions like urinary incontinence and benign prostatic hyperplasia (BPH). By providing less invasive options, drug development has

expanded the range of treatment choices available to patients and healthcare providers.

Advances in drug development have facilitated the creation of combination therapies for complex genitourinary conditions. For example, patients with genitourinary cancers may receive a combination of chemotherapy, immunotherapy, and targeted therapy, resulting in more comprehensive treatment and improved survival rates. These multi-modal approaches are often made possible by innovations in drug development.

### Expanding Treatment Options

The global genitourinary drugs market is witnessing substantial growth, and one of the key drivers behind this expansion is the continuous development and diversification of treatment options. As pharmaceutical companies invest in research and innovation, they are broadening the range of therapies available for genitourinary conditions.

Genitourinary conditions encompass a wide spectrum of diseases and disorders, including urinary tract infections, sexually transmitted infections, erectile dysfunction, prostate cancer, and bladder issues. The diversity of these conditions demands a varied approach to treatment. As pharmaceutical companies develop new drugs and therapies, they cater to the specific needs of patients suffering from different genitourinary disorders.

Advancements in genomics and personalized medicine have allowed healthcare providers to tailor treatments to individual patients. This personalized approach has transformed the way genitourinary conditions are managed. Physicians can select from a range of treatment options based on the patient's genetic makeup, disease stage, and other factors. This not only improves treatment efficacy but also enhances patient satisfaction.

One of the significant developments in the treatment of genitourinary conditions is the advent of targeted therapies. These drugs are designed to specifically target certain molecular pathways or receptors involved in disease progression. For example, in the treatment of prostate cancer, drugs like enzalutamide and abiraterone acetate target androgen receptors, leading to more effective disease management with fewer side effects.

Immunotherapies have emerged as a promising treatment option for various genitourinary cancers. These therapies stimulate the body's immune system to recognize and attack cancer cells. Drugs like pembrolizumab and nivolumab have

shown remarkable success in treating advanced genitourinary cancers, offering patients a new lease on life.

Hormone therapies have been effective in managing conditions like erectile dysfunction and hormonal imbalances within the genitourinary system. These treatments aim to restore hormone levels to their optimal range, addressing the root cause of the problem and providing long-lasting relief to patients.

The treatment of genitourinary infections, such as urinary tract infections (UTIs) and sexually transmitted infections (STIs), relies heavily on antibiotics and antiviral drugs. Advances in microbiology and pharmaceuticals have led to the development of more effective and targeted medications, reducing the duration and severity of infections.

### Rising Healthcare Awareness

The global genitourinary drugs market has been experiencing significant growth, driven in part by the increasing awareness of healthcare and the importance of addressing genitourinary conditions. As individuals become more proactive in managing their health, and as healthcare systems and professionals emphasize the significance of early detection and treatment, the demand for pharmaceutical solutions for genitourinary disorders is on the rise.

In recent years, there has been a noticeable shift in societal attitudes towards discussing and seeking help for genitourinary health issues. Men and women alike are becoming more open to discussing problems such as urinary incontinence, erectile dysfunction, sexually transmitted infections, and genitourinary cancers. This increased awareness encourages individuals to consult healthcare professionals for guidance and treatment.

Healthcare awareness campaigns and initiatives emphasize the importance of early detection and prevention of genitourinary conditions. Regular screenings, check-ups, and health education programs encourage individuals to be proactive in managing their genitourinary health. Early diagnosis often leads to more effective treatment and better outcomes, driving the demand for pharmaceutical interventions.

Historically, stigmatization has discouraged individuals from seeking treatment for genitourinary conditions. However, rising healthcare awareness efforts have helped reduce the stigma associated with these issues. As a result, more people are willing to seek medical attention, contributing to the growth of the genitourinary drugs market.

Healthcare awareness empowers patients to actively participate in their healthcare decisions. Informed patients are more likely to engage with healthcare providers, ask questions, and request specific treatments, including genitourinary drugs. This collaborative approach leads to better-informed choices and improved treatment adherence.

Heightened healthcare awareness campaigns have prompted greater utilization of screening services and diagnostic tests. For example, regular prostate-specific antigen (PSA) tests for prostate cancer, Pap smears for cervical cancer, and tests for sexually transmitted infections are more commonly administered. Early detection and diagnosis often result in the prescription of genitourinary drugs to manage or treat conditions, further boosting market growth.

## Key Market Challenges

### Antibiotic Resistance

One of the foremost challenges in the genitourinary drugs market is the rise of antibiotic resistance. Bacterial infections, particularly urinary tract infections (UTIs), are commonly treated with antibiotics. However, overuse and misuse of antibiotics have led to the development of drug-resistant strains of bacteria. This makes it increasingly difficult to treat UTIs and other genitourinary infections, necessitating the development of new antibiotics and alternative treatment strategies.

### Generic Competition

As patents for existing genitourinary drugs expire, generic versions enter the market, often at significantly lower prices. This increased competition can put pressure on pharmaceutical companies that have invested heavily in research and development, potentially impacting their market share and profitability.

## Key Market Trends

### Immunotherapies on the Rise

Immunotherapies, such as immune checkpoint inhibitors, are gaining prominence in the treatment of genitourinary cancers. These therapies harness the body's immune system to target and destroy cancer cells. As research in this field continues, we can expect to

see more immunotherapeutic options and increased utilization across various genitourinary malignancies.

### Combination Therapies

Combination therapies involving a mix of drugs, immunotherapies, and minimally invasive procedures are gaining traction in the treatment of complex genitourinary conditions. These multi-modal approaches offer a comprehensive strategy to manage diseases such as bladder cancer and prostate cancer.

### Segmental Insights

#### Indication Insights

In the field of genitourinary drugs, market segmentation is based on various medical conditions, including prostate cancer, ovarian cancer, bladder cancer, cervical cancer, renal cancer, erectile dysfunction, urinary tract infections, urinary incontinence, overactive bladder, sexually transmitted diseases, interstitial cystitis, hematuria, and benign prostatic hyperplasia. Among these segments, prostate cancer accounted for the largest share of revenue in 2022. According to a report published by the American Society of Clinical Oncology (ASCO) in March 2023, there were 1,414,259 global cases of prostate cancer diagnosed in 2020.

This growth can be attributed to the availability of a wide range of therapeutic options, such as immunotherapy medications, radiopharmaceuticals, and anti-neoplastic agents, for the treatment of prostate cancer. These treatments offer significant benefits, including improved survival rates, slowed disease progression, and minimal adverse effects, which are leading to increased adoption in the market.

For example, in March 2022, Novartis announced the approval of Pluvicto, a treatment for adult patients with metastatic castration-resistant prostate cancer that is positive for prostate-specific membrane antigen (PSMA-positive mCRPC) and has spread to other parts of the body. This treatment is expected to have a substantial positive impact on the survival rates of patients who have limited treatment options available to them.

### Product Insights

In the realm of genitourinary drugs, market categorization is based on product types, including urological medications, hormonal therapy drugs, gynecological treatments,

anti-infectives, and other miscellaneous products. In 2022, the hormonal therapy sector secured a substantial market share due to the rising incidence of hormonal disorders and shifting lifestyle patterns.

The gynecological segment is projected to experience the most rapid CAGR during the forecast period. This accelerated growth can be attributed to the expanding range of products designed to address reproductive disorders in women within the gynecological product category. The substantial demand for therapeutic solutions in this domain is expected to yield profitable opportunities for segment expansion in the future. Furthermore, the significant focus of government healthcare institutions on improving women's reproductive health is anticipated to offer attractive growth prospects for this segment.

### Regional Insights

In 2022, North America established its dominance in the market, commanding a significant share of the revenue. This can be attributed to several factors, including the widespread prevalence of major genitourinary diseases, the presence of a robust healthcare system, and heightened awareness among the population. Notably, among all genitourinary cancer types, prostate cancer stands out as the second leading cause of cancer-related deaths, contributing significantly to the growing demand for treatments in this region. The American Cancer Society's projection for 2023 anticipates approximately 288,300 new cases of prostate cancer and roughly 34,700 deaths from this disease in the United States alone.

In contrast, the Asia Pacific region is poised to experience the most rapid CAGR in the coming years. This growth is driven by substantial research and development investments from global players and their consistent efforts to introduce branded therapeutics at competitive prices, making them more accessible to a wider population.

### Key Market Players

Abbott Laboratories Inc

Bristol-Myers Squibb Co

Novartis AG

Genentech Inc



F Hoffmann-La Roche AG

Ionis Pharmaceuticals Inc

Eli Lilly & Co

Merck & Co Inc

Pfizer Inc

AstraZeneca PLC

Report Scope:

In this report, the Global Genitourinary Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genitourinary Drugs Market, By Product:

Urologicals

Hormonal Therapy

Gynecological

Anti-infectives

Others

Genitourinary Drugs Market, By Indication:

Prostate cancer

Ovarian cancer

Bladder cancer

Cervical cancer

Renal cancer

Erectile dysfunction

Urinary tract infections

Urinary incontinence & overactive bladder

Sexually transmitted diseases

Interstitial cystitis

Hematuria

Benign prostatic hyperplasia

Genitourinary Drugs Market, By Drug Type:

Hormonal Therapy

Impotence Agents

Urinary Antispasmodics

Urinary pH Modifiers

Uterine Relaxants

Uterine Stimulants

Genitourinary Drugs Market, By Region:

North America

United States

Canada

Mexico

Europe

Germany

United Kingdom

France

Italy

Spain

Asia-Pacific

China

Japan

India

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

## Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genitourinary Drugs Market.

## Available Customizations:

Global Genitourinary Drugs market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

## Company Information

Detailed analysis and profiling of additional market players (up to five).

## Contents

### **1. PRODUCT OVERVIEW**

- 1.1. Market Definition
- 1.2. Scope of the Market
  - 1.2.1. Markets Covered
  - 1.2.2. Years Considered for Study
  - 1.2.3. Key Market Segmentations

### **2. RESEARCH METHODOLOGY**

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

### **3. EXECUTIVE SUMMARY**

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

### **4. VOICE OF CUSTOMER**

### **5. GLOBAL GENITOURINARY DRUGS MARKET OUTLOOK**

- 5.1. Market Size & Forecast
  - 5.1.1. By Value
- 5.2. Market Share & Forecast
  - 5.2.1. By Product (Urologicals, Hormonal Therapy, Gynecological, Anti-infectives, Others)
  - 5.2.2. By Indication (Prostate cancer, Ovarian cancer, Bladder cancer, Cervical cancer, Renal cancer, Erectile dysfunction, Urinary tract infections, Urinary incontinence)

& overactive bladder, Sexually transmitted diseases, Interstitial cystitis, Hematuria, Benign prostatic hyperplasia)

5.2.3. By Drug Type (Hormonal Therapy, Impotence Agents, Urinary Antispasmodics, Urinary pH Modifiers, Uterine Relaxants, Uterine Stimulants)

5.2.4. By Region

5.2.5. By Company (2022)

5.3. Product Market Map

5.3.1. By Product

5.3.2. By Indication

5.3.3. By Drug Type

5.3.4. By Region

## **6. NORTH AMERICA GENITOURINARY DRUGS MARKET OUTLOOK**

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Product (Urologicals, Hormonal Therapy, Gynecological, Anti-infectives, Others)

6.2.2. By Indication (Prostate cancer, Ovarian cancer, Bladder cancer, Cervical cancer, Renal cancer, Erectile dysfunction, Urinary tract infections, Urinary incontinence & overactive bladder, Sexually transmitted diseases, Interstitial cystitis, Hematuria, Benign prostatic hyperplasia)

6.2.3. By Drug Type (Hormonal Therapy, Impotence Agents, Urinary Antispasmodics, Urinary pH Modifiers, Uterine Relaxants, Uterine Stimulants)

6.2.4. By Country

6.3. North America: Country Analysis

6.3.1. United States Genitourinary Drugs Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Product

6.3.1.2.2. By Indication

6.3.1.2.3. By Drug Type

6.3.2. Canada Genitourinary Drugs Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Product

- 6.3.2.2.2. By Indication
- 6.3.2.2.3. By Drug Type
- 6.3.3. Mexico Genitourinary Drugs Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product
    - 6.3.3.2.2. By Indication
    - 6.3.3.2.3. By Drug Type

## **7. EUROPE GENITOURINARY DRUGS MARKET OUTLOOK**

- 7.1. Market Size & Forecast
  - 7.1.1. By Value
- 7.2. Market Share & Forecast
  - 7.2.1. By Product (Urologicals, Hormonal Therapy, Gynecological, Anti-infectives, Others)
  - 7.2.2. By Indication (Prostate cancer, Ovarian cancer, Bladder cancer, Cervical cancer, Renal cancer, Erectile dysfunction, Urinary tract infections, Urinary incontinence & overactive bladder, Sexually transmitted diseases, Interstitial cystitis, Hematuria, Benign prostatic hyperplasia)
  - 7.2.3. By Drug Type (Hormonal Therapy, Impotence Agents, Urinary Antispasmodics, Urinary pH Modifiers, Uterine Relaxants, Uterine Stimulants)
  - 7.2.4. By Country
- 7.3. Europe: Country Analysis
  - 7.3.1. Germany Genitourinary Drugs Market Outlook
    - 7.3.1.1. Market Size & Forecast
      - 7.3.1.1.1. By Value
    - 7.3.1.2. Market Share & Forecast
      - 7.3.1.2.1. By Product
      - 7.3.1.2.2. By Indication
      - 7.3.1.2.3. By Drug Type
  - 7.3.2. United Kingdom Genitourinary Drugs Market Outlook
    - 7.3.2.1. Market Size & Forecast
      - 7.3.2.1.1. By Value
    - 7.3.2.2. Market Share & Forecast
      - 7.3.2.2.1. By Product
      - 7.3.2.2.2. By Indication
      - 7.3.2.2.3. By Drug Type

### 7.3.3. France Genitourinary Drugs Market Outlook

#### 7.3.3.1. Market Size & Forecast

##### 7.3.3.1.1. By Value

#### 7.3.3.2. Market Share & Forecast

##### 7.3.3.2.1. By Product

##### 7.3.3.2.2. By Indication

##### 7.3.3.2.3. By Drug Type

### 7.3.4. Italy Genitourinary Drugs Market Outlook

#### 7.3.4.1. Market Size & Forecast

##### 7.3.4.1.1. By Value

#### 7.3.4.2. Market Share & Forecast

##### 7.3.4.2.1. By Product

##### 7.3.4.2.2. By Indication

##### 7.3.4.2.3. By Drug Type

### 7.3.5. Spain Genitourinary Drugs Market Outlook

#### 7.3.5.1. Market Size & Forecast

##### 7.3.5.1.1. By Value

#### 7.3.5.2. Market Share & Forecast

##### 7.3.5.2.1. By Product

##### 7.3.5.2.2. By Indication

##### 7.3.5.2.3. By Drug Type

## **8. ASIA-PACIFIC GENITOURINARY DRUGS MARKET OUTLOOK**

### 8.1. Market Size & Forecast

#### 8.1.1. By Value

### 8.2. Market Share & Forecast

8.2.1. By Product (Urologicals, Hormonal Therapy, Gynecological, Anti-infectives, Others)

8.2.2. By Indication (Prostate cancer, Ovarian cancer, Bladder cancer, Cervical cancer, Renal cancer, Erectile dysfunction, Urinary tract infections, Urinary incontinence & overactive bladder, Sexually transmitted diseases, Interstitial cystitis, Hematuria, Benign prostatic hyperplasia)

8.2.3. By Drug Type (Hormonal Therapy, Impotence Agents, Urinary Antispasmodics, Urinary pH Modifiers, Uterine Relaxants, Uterine Stimulants)

#### 8.2.4. By Country

### 8.3. Asia-Pacific: Country Analysis

#### 8.3.1. China Genitourinary Drugs Market Outlook

##### 8.3.1.1. Market Size & Forecast



- 8.3.1.1.1. By Value
- 8.3.1.2. Market Share & Forecast
  - 8.3.1.2.1. By Product
  - 8.3.1.2.2. By Indication
  - 8.3.1.2.3. By Drug Type
- 8.3.2. Japan Genitourinary Drugs Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product
    - 8.3.2.2.2. By Indication
    - 8.3.2.2.3. By Drug Type
- 8.3.3. India Genitourinary Drugs Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product
    - 8.3.3.2.2. By Indication
    - 8.3.3.2.3. By Drug Type
- 8.3.4. Australia Genitourinary Drugs Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product
    - 8.3.4.2.2. By Indication
    - 8.3.4.2.3. By Drug Type
- 8.3.5. South Korea Genitourinary Drugs Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product
    - 8.3.5.2.2. By Indication
    - 8.3.5.2.3. By Drug Type

## **9. SOUTH AMERICA GENITOURINARY DRUGS MARKET OUTLOOK**

- 9.1. Market Size & Forecast
  - 9.1.1. By Value
- 9.2. Market Share & Forecast

9.2.1. By Product (Urologicals, Hormonal Therapy, Gynecological, Anti-infectives, Others)

9.2.2. By Indication (Prostate cancer, Ovarian cancer, Bladder cancer, Cervical cancer, Renal cancer, Erectile dysfunction, Urinary tract infections, Urinary incontinence & overactive bladder, Sexually transmitted diseases, Interstitial cystitis, Hematuria, Benign prostatic hyperplasia)

9.2.3. By Drug Type (Hormonal Therapy, Impotence Agents, Urinary Antispasmodics, Urinary pH Modifiers, Uterine Relaxants, Uterine Stimulants)

9.2.4. By Country

9.3. South America: Country Analysis

9.3.1. Brazil Genitourinary Drugs Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Product

9.3.1.2.2. By Indication

9.3.1.2.3. By Drug Type

9.3.2. Argentina Genitourinary Drugs Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Product

9.3.2.2.2. By Indication

9.3.2.2.3. By Drug Type

9.3.3. Colombia Genitourinary Drugs Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Product

9.3.3.2.2. By Indication

9.3.3.2.3. By Drug Type

## **10. MIDDLE EAST AND AFRICA GENITOURINARY DRUGS MARKET OUTLOOK**

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Product (Urologicals, Hormonal Therapy, Gynecological, Anti-infectives, Others)

10.2.2. By Indication (Prostate cancer, Ovarian cancer, Bladder cancer, Cervical cancer, Renal cancer, Erectile dysfunction, Urinary tract infections, Urinary incontinence & overactive bladder, Sexually transmitted diseases, Interstitial cystitis, Hematuria, Benign prostatic hyperplasia)

10.2.3. By Drug Type (Hormonal Therapy, Impotence Agents, Urinary Antispasmodics, Urinary pH Modifiers, Uterine Relaxants, Uterine Stimulants)

10.2.4. By Country

10.3. MEA: Country Analysis

10.3.1. South Africa Genitourinary Drugs Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Product

10.3.1.2.2. By Indication

10.3.1.2.3. By Drug Type

10.3.2. Saudi Arabia Genitourinary Drugs Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Product

10.3.2.2.2. By Indication

10.3.2.2.3. By Drug Type

10.3.3. UAE Genitourinary Drugs Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Product

10.3.3.2.2. By Indication

10.3.3.2.3. By Drug Type

10.3.4. Kuwait Genitourinary Drugs Market Outlook

10.3.4.1. Market Size & Forecast

10.3.4.1.1. By Value

10.3.4.2. Market Share & Forecast

10.3.4.2.1. By Product

10.3.4.2.2. By Indication

10.3.4.2.3. By Drug Type

## 11. MARKET DYNAMICS

- 11.1. Drivers
- 11.2. Challenges

## **12. MARKET TRENDS & DEVELOPMENTS**

- 12.1. Recent Development
- 12.2. Mergers & Acquisitions
- 12.3. Product Launches

## **13. PORTER'S FIVE FORCES ANALYSIS**

- 13.1. Competition in the Industry
- 13.2. Potential of New Entrants
- 13.3. Power of Suppliers
- 13.4. Power of Customers
- 13.5. Threat of Substitute Products

## **14. COMPETITIVE LANDSCAPE**

- 14.1. Business Overview
- 14.2. Product Offerings
- 14.3. Recent Developments
- 14.4. Financials (As Reported)
- 14.5. Key Personnel
- 14.6. SWOT Analysis
  - 14.6.1. Abbott Laboratories Inc
  - 14.6.2. Bristol-Myers Squibb Co
  - 14.6.3. Novartis AG
  - 14.6.4. Genentech Inc
  - 14.6.5. F Hoffmann-La Roche AG
  - 14.6.6. Ionis Pharmaceuticals Inc
  - 14.6.7. Eli Lilly & Co
  - 14.6.8. Merck & Co Inc
  - 14.6.9. Pfizer Inc
  - 14.6.10. AstraZeneca PLC

## **15. STRATEGIC RECOMMENDATIONS**

## **16. ABOUT US & DISCLAIMER**

## I would like to order

Product name: Genitourinary Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product (Urologicals, Hormonal Therapy, Gynecological, Anti-infectives, Others), By Indication (Prostate cancer, Ovarian cancer, Bladder cancer, Cervical cancer, Renal cancer, Erectile dysfunction, Urinary tract infections, Urinary incontinence & overactive bladder, Sexually transmitted diseases, Interstitial cystitis, Hematuria, Benign prostatic hyperplasia), By Drug Type (Hormonal Therapy, Impotence Agents, Urinary Antispasmodics, Urinary pH Modifiers, Uterine Relaxants, Uterine Stimulants), By Region, and Competition

Product link: <https://marketpublishers.com/r/GEEC8E08BD7FEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GEEC8E08BD7FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970